MAVENIR
21.5.2021 05:02:10 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that it’s working with National Telecom Public Company Limited (NT), a state-owned telecommunications company, 5GCT , a local partner specialized in delivering end-to-end 5G Smart Cities and Cisco Systems (Thailand), a leading networking company, to launch the first 5G Open RAN Smart City in Ban Chang, Thailand.
The launch of the 5G Smart City creates synergies between public and private sectors for a fully functional smart city. The city of Ban Chang, is connected to a motorway linking Thailand’s two largest cities: Pattaya and Bangkok. The location is within close proximity to U-Tapao International Airport, Map Ta Phut Industrial Zone and the new master planned Ban Chang Smart City that are strategically important infrastructure for the Digital Economy in Thailand and the Eastern Economic Corridor (EEC). These characteristics make Ban Chang the perfect city to take advantage of 5G use cases across industrial robots, factory automation, remote telemedicine, aviation, logistics and agriculture. Industry leaders are terming the development the ‘Silicon Beach ’ of Asia.
The Ban Chang Smart City 5G Private Network operates on Millimeter wave (mmWave) spectrum, spectrum which is ideally suited for a network operating Internet of Thing (IoT) sensors, drones and smart poles, all applications which require fast data uplink to the core for realtime analysis and city management.
Mavenir provided a cloud-native, open architecture-based Private Network solution that enabled TOT1 to reach the promise of 5G. The software-based platform enabled the transformation of the mobile communication private network into a completely virtualized environment, where devices, applications, and services run on an automated network using open architecture, containers, and artificial intelligence (AI). Mavenir’s end-to-end 5G Open RAN, Millimeter wave (mmWave) radios and 5G Core with Open API technology standards, in-sync with the cloud-native solutions supporting private On-Premise applications delivers Smart City concepts such as real-time diagnostics of traffic, public safety, digital signage and sensitive environmental conditions.
TOT’s IP transport infrastructure vendor and a key Mavenir technology partner, Cisco, provided switching hardware and application services to enable the ‘smart’ components of the 5G solution.
Mavenir’s Aniruddho Basu, GM of its Emerging Business Unit , said “We are proud to be part of this ambitious 5G project which sees a whole city connected on a series of 5G applications running in parallel. Connectivity is at the heart of this deployment - connecting people, communities, government services, and private sector services through local government data combined with new data acquired through Internet of Things (IOT), sensors, drones, and external collected data, to fully analyze it for proper city management and citizen knowledge.”
Commenting on the announcement, Shannon Kalayanamitr, Chief Executive Officer at 5GCT , said “At 5GTC, we are driven to strengthen the potential of Thailand through high speed 5G. The partnership with Mavenir as an infrastructure provider enables us to deliver robust, secure and reliable 5G Private Network infrastructure across enterprises, including smart city applications, industry 4.0 applications - automated industry and modern medicine.”
Taweewat Chantaraseno, Managing Director, Thailand & Indochina, Cisco Systems (Thailand), said “We are delighted to be part of the first 5G smart city in Thailand. With the partnership with Mavenir and Cisco Connected Communities Infrastructure (CCI), the host of Smart City can create a single, secure communications network to support all needs that are simpler to deploy and manage from end-to-end visibility, ranging from smart kiosks and outdoor Wi-Fi, to smart street lighting, parking, waste and more. Smart city infrastructure is enabling efficiency, cost reduction and improved living for city occupants and network infrastructure platform helps create these efficiencies.
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers.
Visit: www.mavenir.com
1 TOT and CAT Telecom recently merged under National Telecommunications Public Company Limited (NT) a Thai Government Telecom service provider
View source version on businesswire.com: https://www.businesswire.com/news/home/20210520005943/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 12:00:00 CEST | Press release
A new platform for dialogue on progress, reflecting a mutual commitment to advancing positive change Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom